Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04782856 · ClinicalTrials.gov registry record · Phase 2
Energy Metabolism in Thyroidectomized Patients
A Phase 2 study of Thyroid Cancer and Hypothyroidism, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT04782856 is a Phase 2 study of Thyroid Cancer and Hypothyroidism that has completed, run by Virginia Commonwealth University. The registered enrollment target is 13 participants, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04782856, a Phase 2 study of Thyroid Cancer and Hypothyroidism, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to measure the changes in energy metabolism (how the body burns energy), cardiovascular function (heart function), and lipid metabolism (cholesterol break down and building) before and after thyroidectomy (surgical removal of thyroid gland) in response to two approved therapies for hypothyroidism: levothyroxine (LT4) or Liothyronine/levothyroxine (LT3/LT4) combination therapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Levothyroxine
- DRUG Liothyronine
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04782856
The ClinicalTrials.gov registry entry for NCT04782856 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04782856 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04782856 about?
NCT04782856 is a clinical study titled "Energy Metabolism in Thyroidectomized Patients". The purpose of this research study is to measure the changes in energy metabolism (how the body burns energy), cardiovascular function (heart function), and lipid metabolism (cholesterol break down and building) before and after thyroidectomy (surgical removal of thyroid gland) in response to two ap...
What is the current status of trial NCT04782856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-10-28. Estimated completion is 2023-04-19.
What conditions does trial NCT04782856 study?
This clinical trial studies the following conditions: Thyroid Cancer, Hypothyroidism, Thyroid Goiter.
What interventions are being tested in trial NCT04782856?
The interventions under investigation include: Placebo (DRUG), Levothyroxine (DRUG), Liothyronine (DRUG).
Who is sponsoring clinical trial NCT04782856?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04782856 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.